Author： Antoniu Sabina Antonela
Publisher： Informa Healthcare
ISSN： 1354-3784
Source： Expert Opinion on Investigational Drugs, Vol.20, Iss.5, 2011-05, pp. : 713-715
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Inhaled mannitol in cystic fibrosis
Expert Opinion on Investigational Drugs, Vol. 16, Iss. 7, 2007-07 ,pp. :
Access to resources
Recommend
Phosphodiesterase Type 5 Inhibitors: Unmet Needs
Current Pharmaceutical Design, Vol. 15, Iss. 30, 2009-10 ,pp. :
Towards a gene therapy for cystic fibrosis lung disease
By Pickles R.J.
Expert Opinion on Investigational Drugs, Vol. 6, Iss. 10, 1997-10 ,pp. :
New indazole derivatives as phosphodiesterase type 4 inhibitors
Expert Opinion on Therapeutic Patents, Vol. 8, Iss. 5, 1998-05 ,pp. :